Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA.
Pediatr Crit Care Med. 2013 Jun;14(5):467-70. doi: 10.1097/PCC.0b013e31828a7451.
IV corticosteroids are routinely prescribed to treat critically ill children with asthma. However, no specific dosing recommendations have been made for children admitted to the PICU. We aim to determine current asthma corticosteroid dosing preferences in PICUs within North America.
Cross-sectional, self-administered survey.
North American PICUs.
Pediatric intensivists working in the United States and Canada.
None.
A total of 104 intensivists completed the survey. Of these, 70% worked in the United States, 67% attended in PICUs with at most 20 beds, and 79% had more than 10 years of PICU experience. The majority of asthmatics were admitted to PICUs based on clinical asthma examination/score or because the patient was receiving continuous albuterol. IV methylprednisolone is prescribed by a large majority of intensivists (96%). Of those who prescribe methylprednisolone, 66% use a starting dose of 4 mg/kg/d, whereas 31% use a starting dose of 2 mg/kg/d, and only 3% use 1 mg/kg/d. The large majority of respondents (85%) use "clinical experience" as their rationale for their preferred dosage. In multivariate logistic regression analysis, only knowledge of the National Heart, Lung, and Blood Institute guidelines was an independent predictor of prescribing an initial corticosteroid dose of 4 mg/kg/d (odds ratio, 3.69 [95% CI, 1.26-10.80]; p = 0.017). Country of practice, years of experience, and PICU size were not associated with corticosteroid dosing preference.
Most intensivists administer methylprednisolone to critically ill asthmatics at doses 2 to 4 times higher than recommended by the National Heart, Lung, and Blood Institute guidelines for hospitalized asthmatic children. The rationale for these decisions is likely multifactorial, but in the absence of evidence-based data, most of them cite clinical experience as their deciding factor. Future research is needed to determine the most appropriate corticosteroid dosage in this critically ill patient population.
IV 皮质类固醇通常被开给患有哮喘的危重症儿童。然而,对于收入 PICU 的儿童,尚无具体的剂量推荐。我们旨在确定北美 PICUs 中目前的哮喘皮质类固醇剂量偏好。
横断面、自我管理的调查。
北美 PICUs。
在美国和加拿大工作的儿科重症监护医生。
无。
共有 104 名重症监护医生完成了这项调查。其中,70%的人在美国工作,67%的人在最多有 20 张床位的 PICUs 工作,79%的人有超过 10 年的 PICU 经验。大多数哮喘患者因临床哮喘检查/评分或因患者正在接受持续沙丁胺醇治疗而收入 PICUs。绝大多数重症监护医生(96%)开 IV 甲基强的松龙。在开甲基强的松龙的医生中,66%使用 4mg/kg/d 的起始剂量,而 31%使用 2mg/kg/d 的起始剂量,只有 3%使用 1mg/kg/d 的起始剂量。绝大多数(85%)受访者将“临床经验”作为他们首选剂量的依据。在多变量逻辑回归分析中,只有对国家心肺血液研究所指南的了解是开初始皮质类固醇剂量 4mg/kg/d 的独立预测因素(比值比,3.69[95%CI,1.26-10.80];p=0.017)。实践国家、经验年限和 PICU 规模与皮质类固醇剂量偏好无关。
大多数重症监护医生给危重症哮喘患者开的甲基强的松龙剂量是国家心肺血液研究所建议的住院哮喘儿童推荐剂量的 2 至 4 倍。这些决定的依据可能是多因素的,但由于缺乏基于证据的数据,大多数人都将临床经验作为决定因素。需要进一步研究来确定这一危重症患者群体最适当的皮质类固醇剂量。